GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sequana Medical NV (XBRU:SEQUA) » Definitions » Gross Margin %

Sequana Medical NV (XBRU:SEQUA) Gross Margin %

: 77.08% (As of Jun. 2023)
View and export this data going back to 2019. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Sequana Medical NV's Gross Profit for the six months ended in Jun. 2023 was €0.30 Mil. Sequana Medical NV's Revenue for the six months ended in Jun. 2023 was €0.38 Mil. Therefore, Sequana Medical NV's Gross Margin % for the quarter that ended in Jun. 2023 was 77.08%.

Warning Sign:

Sequana Medical NV gross margin has been in long-term decline. The average rate of decline per year is -1.6%.


The historical rank and industry rank for Sequana Medical NV's Gross Margin % or its related term are showing as below:

XBRU:SEQUA' s Gross Margin % Range Over the Past 10 Years
Min: 77.55   Med: 79.14   Max: 84.65
Current: 77.55


During the past 9 years, the highest Gross Margin % of Sequana Medical NV was 84.65%. The lowest was 77.55%. And the median was 79.14%.

XBRU:SEQUA's Gross Margin % is ranked better than
87.09% of 798 companies
in the Medical Devices & Instruments industry
Industry Median: 53.615 vs XBRU:SEQUA: 77.55

Sequana Medical NV had a gross margin of 77.08% for the quarter that ended in Jun. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Sequana Medical NV was -1.60% per year.


Sequana Medical NV Gross Margin % Historical Data

The historical data trend for Sequana Medical NV's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequana Medical NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.65 79.61 79.02 79.25 77.79

Sequana Medical NV Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.26 79.31 77.80 77.95 77.08

Competitive Comparison

For the Medical Devices subindustry, Sequana Medical NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sequana Medical NV Gross Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Sequana Medical NV's Gross Margin % falls into.



Sequana Medical NV Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Sequana Medical NV's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=0.7 / 0.923
=(Revenue - Cost of Goods Sold) / Revenue
=(0.923 - 0.205) / 0.923
=77.79 %

Sequana Medical NV's Gross Margin for the quarter that ended in Jun. 2023 is calculated as


Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=0.3 / 0.384
=(Revenue - Cost of Goods Sold) / Revenue
=(0.384 - 0.088) / 0.384
=77.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Sequana Medical NV  (XBRU:SEQUA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sequana Medical NV had a gross margin of 77.08% for the quarter that ended in Jun. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Sequana Medical NV Gross Margin % Related Terms

Thank you for viewing the detailed overview of Sequana Medical NV's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequana Medical NV (XBRU:SEQUA) Business Description

Traded in Other Exchanges
Address
Kortrijksesteenweg 1112 ,bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies and over 750 implants. The company's geographical segments include Switzerland, Germany, the United Kingdom, and the Rest of the world, out of which Germany accounts for the majority of the revenue.

Sequana Medical NV (XBRU:SEQUA) Headlines

No Headlines